Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued ...
What Is Sotyktu, and Why Does It Matter? Sotyktu (deucravacitinib) is an oral selective tyrosine kinase 2 (TYK2) inhibitor used to treat autoimmune inflammatory diseases such as plaque psoriasis in ...
Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...
The factor XIa inhibitor, asundexian (Bayer), has finally achieved the holy grail of reducing thrombotic events without increasing bleeding. In the OCEANIC-STROKE trial, conducted in patients with ...
Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...
ABSTRACT: In Campeche Mexico, corn production is particularly very important due to its large area of medium and high-yield potential. For any plan production, soil fertility needs to be understood ...
Novartis has scored the FDA’s approval for a second BTK inhibitor that’s for a non-cancer indication, teeing off a potential competition with Sanofi down the line. The FDA has blessed Novartis’ ...
Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and ...
College of Resources and Environment, Hunan Agricultural University, Changsha 410128, China ...
Please provide your email address to receive an email when new articles are posted on . Concurrent use of finerenone and empagliflozin reduced urine albumin-to-creatinine ratio for adults with CKD and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results